Uploaded July 2026 | Updated September 2026, 3 weeks ago

---

Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology at UT Southwestern who specializes in treating gastrointestinal cancer, talks about a new investigational drug called daraxonrasib that holds promise in treating pancreatic cancer in patients who stopped responding to other chemotherapies. Note: The Food and Drug Administration approved daraxonrasib in late August 2026 for patients with advanced pancreatic cancer.